In a report released yesterday, David Windley from Jefferies maintained a Buy rating on IQVIA Holdings (IQV – Research Report), with a price target of $293.00. The company’s shares closed last Wednesday at $232.18.
According to TipRanks.com, Windley is a top 100 analyst with an average return of 17.1% and a 70.8% success rate. Windley covers the Healthcare sector, focusing on stocks such as UnitedHealth, Catalent, and Humana.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings with a $293.09 average price target, representing a 28.3% upside. In a report released today, Deutsche Bank also maintained a Buy rating on the stock with a $255.00 price target.
Based on IQVIA Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $3.39 billion and net profit of $261 million. In comparison, last year the company earned revenue of $3.3 billion and had a net profit of $119 million.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
North Carolina-based IQVIA Holdings, Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry. The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More on IQV: